ArticleACS omega2025
Engineered NIR-Responsive Exosomes for Synergistic Photoimmunotherapy of Hepatocellular Carcinoma.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics.Molecular cancer · 2026Review
- Strategies, Challenges and Application Prospects for Exosome Engineering Modifications in Tumor Targeted Therapeutics.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell immunotherapy holds tremendous promise for treating various types of cancer by boosting the infiltration and activity of T cells within tumor tissues. However, efficient recruitment of peripheral T cells to the tumor microenvironment (TME) remains a major clinical challenge. To address this limitation, here, we report an exosomal (EXO) immunotherapy for remodeling the immunosuppressive TME of hepatocellular carcinoma (HCC) into an immunosupportive state in a remotely controllable manner, for which the HCC-secreted exosomes are engineered with CXCL9 chemokine and cypate photothermal transducers (cypate@EXO-CXCL9). The engineered exosomes could efficiently home to the HCC site through homotypic targeting. Upon exposure to near-infrared light, the cypate-mediated photothermal effect readily induces immunogenic death of tumor cells while simultaneously disrupting the exosomes to release CXCL9. The released CXCL9 effectively attracts T cells to the tumor site and is subsequently activated by the HCC-derived antigens and damage associated molecular patterns to mount robust antitumor immunity. This study provides a facile strategy for the remodeling of the immunosuppressive HCC microenvironment, offering an approach for improving immunotherapeutic efficacy of solid tumors in the clinic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.